Effects of a 5-lipoxygenase inhibitor, REV-5901, on leukotriene and histamine release from human lung tissue in-vitro.
REV-5901, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol, is an arylmethylphenyl ether derivative which inhibits 5-lipoxygenase activity of leukocytes. Its effects on the release of leukotrienes, induced by antigen and calcium ionophore, from human lung tissue in-vitro have been examined. At 1 and 10 microM it significantly inhibited the release of leukotrienes induced by both stimuli. At 10 microM it also inhibited antigen-induced histamine release. These results suggest that REV-5901 may be useful in clinical disorders such as asthma in which leukotriene release may be involved.
D001091:Arachidonate Lipoxygenases / Q000037:antagonists & inhibitors*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D006912:Hydroxyquinolines / Q000494:pharmacology*; D066298:In Vitro Techniques; D016859:Lipoxygenase Inhibitors; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D011804:Quinolines; D013189:SRS-A / Q000378:metabolism*
D006912:Hydroxyquinolines; D016859:Lipoxygenase Inhibitors; D011804:Quinolines; D013189:SRS-A; C049740:alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol; D001091:Arachidonate Lipoxygenases